HIV infection and the kidneys, Part I

(1)

PREGLEDI IZ LITERAT URE

ЬЦѬЧќйЬфѳїЬѭдяѯѸѨдѸѳЦЧЬѸдЦѯЭЧѬЬйЬфЧЦйЬфЧ

ЬѻдѻѭЧє

I

_DEO)

·Î¿ÃÑÒÑÍÈ³¦È¬ÆºÈÆº©

Institut za patologiju, Medicinski fakultet, Univerzitet u Beogradu, Beograd

ƭƳƢƵƢƭƴƢƧƳƩƢǊ

ƭǠǖǒǠǝǗǣǟǚǜǑǚǟǦǚǨǚǢǑǟǚǧǓǚǢǥǣǠǞǧǥǞǑǟǗǚǞǥǟǠǖǗǦǚǨǚǹǗǟǨǚǹǗ HIVǜǝǚǟǚǩǜǚǣǗǞǠǘǗǚǣǡǠǺǚǤǚǪǚǢǠǜǣǡǗǜǤǑǢ ǣǚǞǡǤǠǞǑǜǠǹǚǥǜǑǙǥǹǥǟǑǠǪǤǗǼǗǻǗǒǥǒǢǗǔǑưǑǹǩǗǪǼǗǣǗǹǑǓǺǑǑǜǥǤǟǑǚǟǣǥǦǚǨǚǹǗǟǨǚǹǑǢǑǖǑǒǥǒǢǗǔǑǜǠǹǑǹǗǠǒǚǩǟǠǡǠǣǝǗ ǖǚǨǑǣǗǡǣǗǧǚǡǠǤǗǟǙǚǹǗǚǝǚǟǗǦǢǠǤǠǜǣǚǩǟǚǧǑǔǗǟǣǑƲǠǢǗǖǑǜǥǤǟǗǚǟǣǥǦǚǨǚǹǗǟǨǚǹǗǢǑǖǑǒǥǒǢǗǔǑǜǠǖǚǙǓǗǣǟǠǔǒǢǠǹǑǒǠǝǗ ǣǟǚǜǑǹǑǓǺǑǣǗǟǗǦǢǠǡǑǤǚǹǑǚǙǑǙǓǑǟǑǣHIVǜǠǹǑǹǗǣǜǝǗǢǠǙǚǢǑǹǥǼǗǡǢǚǢǠǖǗǚǣǞǑǤǢǑǣǗǠǒǝǚǜǠǞǦǠǜǥǣǟǠǣǗǔǞǗǟǤǟǗǔǝǠǞǗǢǥ ǝǠǣǜǝǗǢǠǙǗǜǠǹǑǚǞǑǟǑǹǡǢǠǔǢǗǣǚǓǟǚǹǚǤǠǜ

ƭǺǥǩǟǗǢǗǩǚHIVǟǗǦǢǠǡǑǤǚǹǑǚǙǑǙǓǑǟǑǣHIVǦǠǜǥǣǟǠǣǗǔǞǗǟǤǟǑǔǝǠǞǗǢǥǝǠǣǜǝǗǢǠǙǑǑǜǥǤǟǑǚǟǣǥǦǚǨǚǹǗǟǨǚǹǑǒǥǒǢǗǔǑ

UVOD

ÇÎ´Ê»Î§ÎÀÑ§ÃÀÊ¨ª²ÎÃ¨ÒÑÔ»Ñ»ÑÃÑµ¶ ÀÔÊ¶Î¾¸ÎÃÑ ÒÑÉÑÒÃ§¨µÑ¨ÒÖ»®¨µÔ¨¿¶ÀÎ§ª¶

§ÑÒ¨§¶ÒÎÃÖ¨®¨µÒ®¨µ HIV´¨Ò¨¸ÎÀÃÑ¾¨¾¶

¾¿²»ÎÃÎÀÎ¾ÑÎ¾Î¸¸¨ªÎÃÀ¨Ã§Î²ÑÎ¾¨Ê¨ÉÎ¼Ê ±ÒË±¶Ê¨§²ÎÃ¨ÒÎ¾µÑÔ¹ÒµÉ¿Ô¨¿ÑÃ¶ »Î§À»ÎÃÎÔ¨ª¾Î¸ÀÒ¨»ÑÎÉ¨À¶µ¶¨É¿Î§ÒÒÑ¾¶ ¾¿Ó¨§Ñ£¿ÑÃÎÔ¨§Ñ»Îµ¨À¶À¸Ã¨¸¨ÎÉ¨ÀÑÒµ´¨ÊÑÔ ÀÉ»ÊÑ¿É¿Î§ÒÑ»ÎµÀ¶¶ÊÔ¿±Ò»ÎÃ¾Î¸ÀÒ¨»Ñ»ÎÃ

»Îµ¨ªµ¾¨¸ÑÉÎÊÔ¿±ÒÑHIV¨ÒÖ»®¨µÑ#%¦Ñ»ÎÀ¶

kao posledicaHIV¨ÒÖ»®¨µÒÑ¾¶¾¿Ó¨§ÑÎÉ¨ÀÑÒ¨

Ñ»¶ÊÒÑÊ¶¾¶¸À»ÑÒ»¿ÎÓÑ»ÎµÑ§ÎÁÒÑÀÊÑÊ¨»ÑÎÉÎ À¸Ã¨®Ñª¨ÉÎÊÒÓ¨µÃª¨Ã¿ÑÊÑ®¨µÊµª¨ÉÎÔÎ¸§¨µ À»Î²¼Î»ÑÀÉÀ¿ÑÃ¨Î»ÎÒÊ¿ÑÀÊÒ¨ªÑ²ÒÀÑ»Îµ¨À»Î ¿¨ÀÊ¶Ã¨µÑ²ÒÎÀÊ¨´»ÀÔ¿ª¨¸¨À§ÎÁ¿ÑÓÔ¨Ê¨»ÑÎ ÉÎÀ¸Ã¨®ÑÉ¿¨§ÒÒÖ¿ÎÊÎ»À¨´Ò¨ª¸»ÎÔÑ#% alergijski intersticijski nefritis, koji nastaje ¶À¸ÃÉ¿¨§Ò¸»ÎÔÑ»Îµ¨À»Î¿¨ÀÊ¶¸´ ¶À¨Ã »ÑÎ¼ÊÎÀ¶Ê¿¨§ÊÎÉ¿¨§À¶¸ÖÑ§ÊÎ»ÀÑÓÎ¸ÒÖ¿Î »Ñ¸®¨ÒÎÓÑ»Ñ¿®¨ÒÎ§¿ÒÑ¸Ò¨ª¤¸¨µÑ»¿¨ÉÊÎ »Î»Ò¨ÑÉÀ®À¨¿ÑÓ¸¨´¨ÊÉ¿Î§ÒÒÑ²¸Î§¿¶¸¨ §Ñº¨¼²ÎÃ¨¼ Ñ¨ÀÉ¨Ê¨ÔÑ ÑÀ¶ÉÎ»ÑÓÑ¸ÑÃÑ¶À»¸Î É¶À¨Ã»ÎÃ¾Î¸ÀÒ¨»ÑÃÎ¸ÑÓ¨ÃÎÎ¼Ê¤ Ñ¾¶ ¾¿²Ñ»ÎµÀ¨ÀÉÎ¹ÑÔÑ»ÑÎÒÖ¿ÎÉÑÊ¨µÑ¨ÓÑÓÔÑÒÑÀ

HIV#%»ÎµÑÎ¾¶ªÔÑÊÑÑ¸¿²¨µÀ»¨¨ÒÊ¿ÀÊ¨®¨µÀ»¨

ÒÖ¿¨Ê¨À ¨ÓÑÓÔÑÒÉ¿¨§ÒÎ§¸»ÎÔÑ¨§¶ÒÎ»Î§É¸» ÀÒ¨²¸Î§¿¶¸ÎÒÖ¿¨Ê¨À¨ÖÎ»¶ÀÒÎÀ²§ÒÊÒ¶²¸Î§ ¿¶¸ÎÀ»¸¿ÎÓ¶ÀÉ¨Ê¨ÔÑ ÑÀ¶ÉÎ»ÑÓÑ¸ÑÃÑÒÉÎÀÊÎ µ¨»Î¿¸Ñ®¨µÑ¨Ó§±¶¿ÑÓÔÎµÑÒÖ¿ÎÉÑÊ¨µ¨ÓÑÓÔÑÒÀ

HIVÀÊÑ¿ÎÀÊ¨Î¾Î¸¸¨ªÎÀÎ¾ÑÊ¿ÑµÑ ÑHIV¨ÒÖ»®¨

µ¨¸¨Ê¨ÉÑÎÉÎ¿Ê¶Ò¨ÀÊ¨´»¨ÒÖ»®¨µ#%

ЦЧѬѭѯѱѳлЬфѳЬьѳьїѳЦѳяHIV

£¾¿ÎµÒ¨§¿ÑÃÎÔ¨§ÑÎÉ¨ÀÑÒÀ¶»¸¨Ò¨´»§ÑÒ¨ ÖÀÊÑ®¨µ»ÎµÀµÑÔ¹Ñµ¶»ÎÃ¾Î¸ÀÒ¨»ÑÀ»¸ÑÀ¨´ÒÎ§ nefropatijom izazvanom sHIV#%£ÀÔ¨§¨À

Ê¿ÑÁ¨ÔÑ ¨§Ñ¾Î¸ÀÒ¨»ÑÀÎÔ¨§Î¾Î¹ §Ê¨É¨´Ò À¶É¿ÎÊ¨Ò¶¿¨µÑ »ÎµÑ´ÀÊÎÃÎÀÊ¨ÁÔ¸¨»Ô¿ÃÒÎ ÀÊ¨¨¨ÒÀ¶Ö¨®¨µÒ®¨µÑ¿ÑÃÑ¾¶¾¿²Ñ°ÑÒ¨§¹¨ÔÎµ ÃÑÀ»ÎÃ¾Î¸ÀÒ¨»Ñ»ÎÃ»Îµ¨ªÀ¿ÑÓÔ¨µÒÖ¿ÎÊÀ»¨ À¨ÒÃ¿Î§¿Ê»Î¶ÊÔ¿±¶µ¶ª¨É¿ªÎ¸ÀÊ¿Î¸§¨µÑ¨²

Ò¿Ñ¸¨ÓÎÔÑÒ¨ÎÊÎ®¨#%¼ÊÎÀÊ¶§Ñ´¨À§Ñ § À¨ÒÊÓ¸¨ÉÎÉ¿ÎÊ¨ÒÑ¶µÊ¿¨»ÎµÀµÑÔ¹Ñ¶À»¸ÎÉ¶

HIV¨ÒÖ»®¨µ£¸¨Ê¿ÑÊ¶¿¨ÉÎÀÊÎµ¿ÑÓ¸¨´¨Ê¨ÉÎ

ÃÑ®¨Î¶´ÀÊÑ¸ÎÀÊ¨µÑÔ¹Ñ Ñª¨É¿ÊÒÓ¨µ»ÎÃ¾Î¸ snika s nefropatijom izazvanom sHIVÎ»ÀÉ¿§Ñ

¿Ó¶¸ÊÑÊ¨§Ñ¨ÀÊ¿ÑÁ¨ÔÑ ÑµÃÒ²¿¶É¨ÀÊ¿ÑÁ¨ÔÑ´Ñ ª¨É¿ÊÒÓ¨µÑµÑÔ¹Ñ»ÎÃÎ¾Î¸¸¨ªÎÀÎ¾ÑÃ¿¶²¨ Ñ¶ÊÎ¿¨À§ÑÊ¿Ñµ¶ÃÑµÊÑµÉ¿Î®ÒÑÊÔ¿¸Î§Ñ¸¨5ÀÔ²Ñ #%ÒÑÀ¶É¿ÎÊÔ¨ÀÎ»Î§É¿Î®ÒÊ¶ÒÎ¿§ÎÊÒÓ¨Ô Ò¨ª¨ª¨ÉÎÊÒÓ¨ÔÒ¨ª¾Î¸ÀÒ¨»Ñ½ÎÃÉÎµÃ¨Ò¨ª¾Î ¸ÀÒ¨»ÑÓÑ¾¸ÁÒÀ¶¨§¨»¿Îª§ÑÊ¶¿¨µÑ¨ÀÊ¿¨¸ ÒÑÉ¨µ¶¿¨µÑ#%£¸Ê¿ÑÓÔ¶´Ò¨§É¿²¸ÃÎ§µ¶ÊÔ¿ ±ÒÎÃÑÀ¶¾¶¾¿Ó¨ÎÔ¨ª¾Î¸ÀÒ¨»ÑÉÎÉ¿ÑÔ¨¸¶¶Ô¤Ñ Ò¨¨ª¨É¿ªÎ²Ò¨#%Æ¾Î¹ ¾¶¾¿²ÑµÒÑµ´ ¼¤Ö¶¸§¨ÒÑÒÊÒÎ²ÊÎ»Ñ¨ÓÑÔ¿¼ÑÔÑÀ¶¿§¨µÎ§ÉÎ À¸Ò»Î¸¨»ÎÒÃ¹Ñ¨¸¨Ê¿¨´Ê¨¿¨§À®ÑÎÃµÑÔ¹Ñ ÑÉ¿Ô¨ªÀ¨§ÉÊÎ§Ñ#%

Ñµ´¼¤ÑÉÑÊÎ§Î¿ÖÎ¸Î¼»ÑÉ¿Î§ÒÑ»ÎµÑÀÎÉ¨À¶ µ»ÎÃ¾Î¸ÀÒ¨»ÑÀÑÒÖ¿ÎÉÑÊ¨µÎ§¨ÓÑÓÔÑÒÎ§ÀHIVje »Î¸ÑÉÀÒÑÖÎ¿§ÑÖÎ»¶ÀÒÎÀ²§ÒÊÒ²¸Î§¿¶¸ÎÀ»¸ ¿ÎÓ Ä³·³#%¦¿§¨Ò<»Î¸ÑÉÀÒÑ=ÎÓÒÑ´ÑÔÑ¨Ó¿ÑÁ Ò¶¿Ê¿Ñ»®¨µ¶¨¸¨ÒÑ¾¨¿Ñ ²¸Î§¿¶¸Î¾ÑÓÑ¸Ò§§ ¾¿ÑÒ ·ÍË¼ÊÎ¨§ÑÓÑÉÎÀ¸Ã¨®¶Î»¸¶Ó¨µ¶¸¶§ ÒÑ²¸Î§¿¶¸À»¨ª»ÑÉ¨¸Ñ¿Ñ»ÎµÑ§ÎÁ¾¨Ê¨À²§ÒÊ ÒÑ¨¸¨´¼¤²¸Î¾Ñ¸ÒÑ£ÓÑªÔÑ¤Ò¨§À²§ÒÊ¨§Ñ É¿Ñ»Ê¨´ÒÎÀÒ§ÎÁ¶Î´¨Ê¨§ÓÑÒ²¨µÀ»ÑÉ¿Î¸¨Ö ¿Ñ®¨µÑ»ÑÎÒ¨ª¨µÑ¸¨ÒÎÓÑ·ÎÊÎÔÎ»ÎÃÀÔ¨ª¾Î¸ÀÒ¨ »Ñ¶Î´ÑÔÑµ¶À¨Ó¿ÑÁÒÑª¨É¿Ê¿ÎÖ¨µÑ¨ª¨É¿É¸ÑÓ¨ µÑÔ¨À®¿Ñ¸Ò¨ªÉ¨Ê¸Ò¨ª¤¸¨µÑ»Îµ¨ÓÒÑÃ»Î¸ÑÉ ÀÒÎ¨Ó§ Ò¨ª¸Î¾¶¸¶ÀÑÔÑÀ»¶¸Ñ¿ÒÎ²»¸¶¾ÊÑ²¿Ñ Ã®¸¶¸Ñ¿ÒÉÎ¸¶§À´ÑÀÊÖÎ¿§Ñ®¨µº¨À®¿Ñ¸Ò É¨Ê¸Ò¤¸¨µ ÉÎÃÎ®¨Ê¨À¶ÓÒÑÊÒÎ¨Ó§ Ò¨ ªÎÔÎµÃ¿Îµ¶Ô¤ÑÒÎ¨ÔÓ¨»¶¸Ñ¿ÒÎÑ¶®¨ÊÎÉ¸ÑÓ§¨ ÀÒÑ¸ÑÓ¾¿ÎµÒÉ¿ÎÊ¨ÒÀ»¿ÀÎ¿É®¨ÎÒ»ÑÉ¹¨® »ÑÎ¨Ô¤¨¾¿Îµ§¨ÊÎÓÑÀÉ¨Ê¨ÔÑ Ñ¶»Îµ¨§ÑÀ¶»Î ¿¨¼¤ÒÑPCNA proliferation cell nuclear antigenÑÒÊ¨

tela pokazala su visok proliferacioni potencijal ÉÎÃÎ®¨ÊÑ#%ÅÊ»ÎÀÒÑ²¸Î§¿¶¸¨§Ñ§Î²¶¶ÊÔ¿Ã¨ Ê¨¸Ó¨µ»ÎµÀ¶Ê¨É¨´ÒÓÑÄ³·³»ÑÎ¼ÊÎÀ¶ÉÎÔ ¤Ñ §ÓÑÒ²¨µÀ»Î²§ÑÊ¿¨»ÀÑÃ¨À»¿ÊÒ¨À²§ÒÊÒ¨ ÎÁ¨¹®¨ª¨µÑ¸¨ÒÎÓÑ¨»ÑÉÀ¶¸ÒÑÃªÓ¨µ

½ÎÃ²ÎÊÎÔÎÀÔ¨ª¾Î¸ÀÒ¨»ÑÀÒÖ¿ÎÉÑÊ¨µÎ§¨ÓÑ zvanom sHIV¶Î´ÑÔÑÀÒÀ»¸ÑÃ¨Ó§±¶¾¸ÑÁ¨ªÉ¿Î

(2)

ƴƳƲƴƭƫƢƳƸƫƤƪƢƹƨƮƱƭƶƲưƱƮƨƭƢƳƴƵƤƱ

Ê¶¾¶¸Î¨ÒÊ¿ÀÊ¨®¨µÀ»¨ªÉ¿Î§ÒÑ»ÎµÎ¾¶ªÔÑÊÑµ¶Ã ²Ò¿Ñ®¨µ¶¨¿²Ò¿Ñ®¨µ¶É¨Ê¸Ñ»ÑÒÑ¸¨¤ÑÊ¶¾¶¸ À»¶ÑÊ¿ÎÖ¨µ¶Ã§¨Ö¨¾¿ÎÓ¶¨ÒÊ¿ÀÊ¨®¨µ¶§Ñ¶»Î µ§À´ÀÊÎÒÑ¸ÑÓÔÎ§Ñ¨Ó¿ÑÁÒ¨ÓÑÉÑ¹ À»¨¨Ò Ö¨¸Ê¿ÑÊ¨Ó¿ÑÁÒÎÀÊÊ¶¾¶¸Î¨ÒÊ¿ÀÊ¨®¨µÀ»¨ªÉ¿Î §ÒÑµ§ÒÎ²ÎÔ¤Ñ»ÎÃ¾Î¸ÀÒ¨»ÑÀÎÔ¨§Î¾Î¹ § Ò²Î»ÎÃ¾Î¸ÀÒ¨»ÑÀÑÄ³·³¶À»¸ÎÉ¶ª¿Î¨ÒÀ»Ò Ö¿ÎÉÑÊ¨µ¨¸¨ÎÀÎ¾ÑÎ¾Î¸¸¨ªÎÃ¨Ã¨ÎÉÑÊÀ»Ä³·³ ÒÊ¿ÀÊ¨®¨µÀ»¨¨ÒÖ¨¸Ê¿ÑÊ¨À¶ÀÑÀÊÑÔ¹Ò¨É¿Ê

ÁÒÎÎÃ¸¨§ÖÎ®¨ÊÑ¨ÊÎÉ¿ÃÎ§¨ÒÑÒÊÒÎCD8+_T_¤

¸¨µÑÉÎ¿Ã»Îµ¨ªÀÒÑ¸ÑÓ¨¨§Ñ ¨¾¿ÎµÉ¸ÑÓ§Î®¨ÊÑ monocita iB¸¨§ÖÎ®¨ÊÑº¤µÉÎ§Ò¶ÊÎÃÑÀ»ÎÃ

Ô¤¨Ò¾Î¸ÀÒ¨»Ñ¶Î´ÑÔÑµ¶Ã²Ò¿Ñ®¨µÑ¨ÑÊ¿ÎÖ¨µÑ É¨Ê¸Ñ»ÑÒÑ¸¨¤ÑÆÀ¨§ÊÎ²Ñ´ÀÊÎÀ¶ÊÔ¿±¶µ¨§¨ »¿Î®¨ÀÊ¨´ÒÑÃ¨¸ÑÊÑ®¨µÑÊ¶¾¶¸Ñ¿Ò¨ª¸¶§ÒÑ¶»Îµ¨ §ÑÀÒÑ¸ÑÓ¾¸ÑÒ´Ô¨ÒÑÀÊ¨®¨¸¨ÒÃ¿¨ÀÑÀÊÑÔ¹Ò¨ ÎÃÑ¸¾¶§¨ÒÑ¨¨§¶ÒÎ²¸Î¾¶¸¨ÒÑÑ¸¨Ò¨»ÑÃÑ¨¦Ñ§ ÂÎ¿ÀÖÑ¸ÎÔÎ² TammHorsfallÉ¿ÎÊ¨ÒÑ#%

U skorije vreme kodHIVÉÎÓ¨Ê¨ÔÒ¨ªÎÀÎ¾ÑÎÉ¨

ÀÑÒµÒÑÀÊÑÒÑ»ÉÎÀ¾ÒÎ²Ê¨ÉÑÑ»¶ÊÒÎ²¨ÒÊ¿ÀÊ¨®¨µ skog nefritisa poznat kaoDILS diffuse infiltrative lymphocytosis syndromeDILS µ À¨ÀÊ§À»Ñ ¾Î¸ÀÊ

»ÎµÑÀµÑÔ¹Ñ»ÎÃ§Ñ¸Î²¾¿ÎµÑ¾Î¸ÀÒ¨»Ñ¨ÒÖ¨®¨¿Ñ nih sHIVÑÎÃ¸¨»¶µÀ¨Ó¿ÑÁÒÎ§¨ÒÖ¨¸Ê¿Ñ®¨µÎ§

É¿ÊÁÒÎCD8 T¸¨§ÖÎ®¨ÊÑ»Îµ¨É¿ÎÁ¨§Ñµ¶¨ÒÊ¿

ÀÊ¨®¨µ¶§É¹¶ÔÑ´Ò¨ªÁ¸ÓÃÑÉ¸¶¤Ñ²ÑÀÊ¿Î¨ÒÊÀÊ¨ ÒÑ¸ÒÎ²Ê¿Ñ»ÊÑ¨¾¶¾¿²Ñ#%½ÎÃÎÔ¨ª¾Î¸ÀÒ¨»Ñ »¸¨Ò¨´»¨ÀÒÑµ´¼¤¿ÑÓÔ¨µÑ¿ÒÑ¸ÒÑÊ¶¾¶¸À»ÑÑ®¨ doza tipIV·ÒÊÀ»Ñ¨ÀÉ¨Ê¨ÔÑ Ñ»ÎµÑÀ¶Ò»Î¸¨»Î

ÉÎÀ¸Ã ¨ª²ÎÃ¨ÒÑÔÎ§ÑÑ»Ê¶¸ÒÑÎÊ»¿¨¸ÑÀ¶²ÒÊ sku predispoziciju za razvoj nefropatije izazvane

sHIV»ÎÃÎÀÎ¾ÑÓÑ¿ÑÁÒ¨ªÎÔ¨§Ô¨¿¶ÀÎ§½ÎÃ

¾Î¸ÀÒ¨»ÑÀÑ¾¶¾¿ÁÒ¨§§ÑÒ¨ÖÀÊÑ®¨µÑ§ÑÎÊ»¿¨ ven jeHLADR5alelDRB1*1102iliHLADR6alel

DRB1*1301#%

§¶ÒÎÖ¸¶Î¿À®ÒÊÒ¨ ÒÑ¸ÑÓ ÒÑ Ê»¨Ô¶ ¾¶¾¿²Ñ »ÎÃÎÀÎ¾ÑÎ¾Î¸¸¨ªÎÃÀ¨ÃµÒÀÉ®¨Ö¨´ÑÒ¢ÀÊÎ À¶ÒÀ»¸¿ÎÊ¨´Ò¨§²¸Î§¿¶¸¨§Ñ§Î²¶¶Î´¨Ê¨Ã pozitiIgM,C3ÑÒ¼ÊÎ¿±C1£¨ÒÊ¿É¿ÊÑ®¨µ¨

¨§¶ÒÎÖ¸¶Î¿À®ÒÊÒ¨ªÒÑ¸ÑÓÑÊ¿¾Ñ¾¨Ê¨ÔÎ§ÑÎ¾Ñ Ó¿¨ÔÃÑÀ¿ÀÎ¿É®¨ÎÒ»ÑÉ¹¨®É¿ÎÊ¨ÒÑ»ÎµÀÉÎ Ó¨Ê¨ÔÒÎ¾ÎµÀÑÒÊ¨Ê¸¨§ÑIgG,IgA¨Ñ¸¾¶§¨ÒÑÑ´

ÀÊÎÀÒÑ¸ÑÓ¶®¨ÊÎÉ¸ÑÓ§¨Ô¨À®¿Ñ¸Ò¨ª¤¸¨µÑÒ É¿ÎÊ¶§Ñ´»ÑÎ¨§¶ÒÀ»¨ÃÉÎÓ¨Ê¨¶²¸Î§¿¶¸¨§Ñ

¸»Ê¿ÎÒÀ»Î§¨»¿ÎÀ»ÎÉÀ»Î§ÑÒÑ¸¨ÓÎ§Ê»¨ÔÑ¾¶ ¾¿²Ñ»ÎÃÎÀÎ¾ÑÎ¾Î¸¸¨ªÎÃÒÖ¿ÎÉÑÊ¨µ¨ÓÑÓÔÑÒ sHIV¶Ô»À¶Î´ÑÔÑµ¶»Î¸ÑÉÀÒÉ¿Î§ÒÒÑ²¸Î§¿¶

¸¨§Ñ»ÎµÀ¨ÀÉÎ¹ÑÔÑµ¶¶Ô¨Ã¶ÒÑ¾¨¿Ñ Ñ¨À»Ô¿´Ñ ÔÑ ÑÀ²§ÒÑÊÑ·ÍË¶À»¸¿ÎÊ¨´Ò¨§¨¶ÒÀ»¸ ¿ÎÊ¨´Ò¨§À²§ÒÊ¨§ÑµÑÔ¹Ñµ¶Àª¨É¿Ê¿ÎÖ¨µÑ¨§¨ »¿ÎÔ¨¸¶ÀÒÑ Ê¿ÑÒÀÖÎ¿§Ñ®¨µÑ Ô¨À®¿Ñ¸Ò¨ª ¤¸¨µÑ »ÑÎ ¨ À¸É¹ ¨ªÎÔ¨ª É¿ÀÊÑÀÊ¨ª É¿ÎÃ¶ÁÊÑ»Ñ ÅÊ»ÎÀ¶²¸Î§¿¶¸¨§Ñ§ÓÑÒ²¨µ¶§¶¨À¶¾ÒÃÎÊ¸ ÒÎÎÃÒÎÀÒÎÉ¿¨§§¾¿ÑÒÎÓÒÎÃ¶ÁÉ¿¨Ö¿Ò¨ª»Ñ É¨¸Ñ¿Ò¨ªÉÊ¹¨ÎÉ¨À¶µ¶§Ñ¸¨²¶ÀÊ¨ÃÉÎÓ¨Ê¨½ÎÃ Ô¨¼ÎÃ¾¨ÎÉÀ¨µÀ»¨ªÒÑ¸ÑÓÑ¶²¸Î§¿¶¸¨§Ñ¨Ò ÃÎÊ¸¶»¿ÔÒ¨ªÀ¶ÃÎÔÑÀ¶Î´ÑÔÑµ¶¾¿ÎµÒÊ¶¾¶¸Î¿Ê¨ »¶¸Ò¨Ò»¸¶Ó¨µÆÒÀÀÑÀÊÎµÎÃÊ¶¾¶¸Ñ¿Ò¨ªÀÊ¿¶»

Ê¶¿ÑÉ¿´Ò¨»ÑÎÃnm»ÎµÀ§±¶ÀÎ¾ÒÎÀÉÑµÑµ¶

ÑÀ§¼ÊÒÀ¶¶Ã¨¸ÑÊ¨¿ÑÒ¨§®¨ÀÊ¿ÒÑ§ÑÒÃÎÉ¸Ñ Ó§ÑÊÀ»Î²¿Ê¨»¶¸¶§Ñ³¸¨´Ò¨Ò»¸¶Ó¨µÀ§Î²¶ÒÑ ¤¨¨¶®¨ÊÎÉ¸ÑÓ§¨¸¨§ÖÎ®¨ÊÑ»Îµ¨ÀÒÑ¸ÑÓ¶¨Ò Ö¨¸Ê¿ÑÊ¶»ÑÎ¨¶®¨ÊÎÉ¸ÑÓ§¨ÉÎÃÎ®¨ÊÑÅ±À§Î

²¶¶Î´¨Ê¨²¿ÑÒ¶¸¨¿ÑÒÑÃ²Ò¿Ñ®¨µÑª¿Î§ÑÊ¨ÒÑ¶µ Ã¿¶¨ÒÊ¿ÀÊ¨®¨µÀ»¨ª¨Ê¶¾¶¸À»¨ª¤¸¨µÑ®¨ÊÎ§ ²Ñ¸ÎÔ¨¿¶ÀÒ¨Ò»¸¶Ó¨µ¨ÉÎÔ¤ÑÒ¾¿ÎµÒ¶»¸¶ÀÒ¨ª ¸»Ê¿ÎÒÀ»¨²¶ÀÊ¨ªÊ¸Ñ¼Ñ®Ñ#%

ËÒÎ²¨¨ÀÊ¿ÑÁ¨ÔÑ´¨À¶ÉÎ»¶¼Ñ¸¨ÃÑÎ¾µÑÀÒ§ ªÑÒ¨ÓÑ§ÒÑÀÊÑÒ»ÑÎÃÒÎÀÒÎÉÑÊÎ²ÒÓ¶ÒÖ¿ÎÉÑÊ¨ je izazvane s HIVÇ¿§Ñ§¨¼¹ ¶µÃÒ¨ªÎÒÑ¾¨

§Î²¸Ñ ¾¨Ê¨ ÉÎÀ¸Ã¨®Ñ Ã¨¿»ÊÒÎ² Î¼Ê¤ Ñ ®¨ÊÎ ÉÑÊÀ»¨§ Ö»Ê¨§Ñ É¨Ê¸Ò¨ª Ô¨À®¿Ñ¸Ò¨ª ¨ Ê¶ ¾¶¸À»¨ª¤¸¨µÑ¶À»¸ÎÉ¶Ô¨¿¶ÀÒ¨ÒÖ»®¨µÉÑ¿Ò ª¨§Ñ¾¶¾¿²ÑÇ¿§Ñ§¨¼¹ ¶Ã¿¶²¨ªÉ¿Î§ÒÒÑ ÀÊÑµ¶¨ÒÃ¨¿»ÊÒ¨§Î¼Ê¤ §¾¶¾¿²Ñ»ÎµÒÑÀÊÑµ ÊÑ»Î¼ÊÎ¶¤¸¨µ¾¶¾¿²ÑÃÎÀÉÔÑµ¶§Î¸»¶¸¨ÀÑÔ¨ ¿¶ÀÒ¨§ÉÑ¿Ê¨»¶¸Ñ§Ñ»Îµ¨ÀÒÑ¸ÑÓ¶®¨¿»¶¸Ñ®¨µ¨ Ñ»¿Ñµ¶Ò»¨¨ÀÊ¿ÑÁ¨ÔÑ´¨À§ÑÊ¿Ñµ¶ÃÑµ§ªÑÒ¨ ÓÑ§Î¼Ê¤ Ñ¾¶¾¿²Ñ¨ÒÃ¨¿»ÊÑÒ¨ÃÑµÉÎÀ¸Ã¨ ®ÑÎÀ¸Î¾Ñ±Ñ Ñ®¨ÊÎ»¨ÒÑÎÃÀÊ¿ÑÒÓÑ¿ÑÁÒ¨ª¸¨§ focita ili monocita, kako u cirkulaciju, tako i u ÉÑ¿Òª¨§¾¶¾¿²Ñ¶»Îµ§ÀÒÑ¸ÑÓ¶Ô¨Ã¶¨ÒÖ¨¸ Ê¿ÑÊÑº¿¸ÎÔ¿ÎÔÑÊÒÎ¨Ó²¸ÃÑÊ¶§Ñ´ ÃÑ¶¿ÑÓÔÎµ¶ nefropatije izazvane sHIVÔÑÁÒ¶¶¸Î²¶¨§Ñµ¶§ªÑ

Ò¨Ó§¨»ÀÉ¿À¨µ²ÒÑ¸Î®¨¿ÑÒ¨ªÒÑ¤¸¨µÑ§ÑÉÑ¿Ò ª¨§Ñ¾¶¾¿²Ñ»Îµ¨À¶¨Ó§ Ò¨®¨ÊÎ»¨Ò¨§Ñ¨ÖÑ»ÊÎ ¿¨§Ñ¿ÑÀÊÑÆÔ¨É¿Î®À¨ÃÎÔÎÃÃÎ¨ÒÊ¿ÀÊ¨®¨µÀ» Ö¨¾¿ÎÓ¨ÉÎµÑ´ÑÒÎ²ÀÊÔÑ¿Ñ Ñ²¸Î§¿¶¸À»Î²§ÑÊ¿¨» ÀÑÓ²¸ÃÑÉ¿¨¿ÎÃÒÎÃÑ»¹¶´Ò¶¶¸Î²¶¶ÒÑÀÊÑÒ»¶Ò fropatije uHIVinfekciji ima priroda odgovora ÃÎ§Ñ¤¨ÒÑÒÑÔ¨¿¶ÀÒ¶¨ÒÖ»®¨µ¶

»¨ ¨ÀÊ¿ÑÁ¨ÔÑ´¨ ¨ÀÊ¨´¶ §Î²¶¤ÒÎÀÊ Ã¨¿»ÊÒ

¨ÒÖ»®¨µ¤¸¨µÑ¾¶¾¿²ÑÀHIV½ÑÎ®¨¹ÒÎ§ÀÊÎ

direktne virusne infekcije navodi se mezangijska ¤¸¨µÑ¶²¸Î§¿¶¸¶ËÓÑÒ²¨µÀ»¤¸¨µ¨§Ñµ¶§ÒÎ²Î À¸¨´Ò¨ªÎÀÎ¾¨ÒÑÀ§ÎÒÎ®¨Ê¨§ÑÎ»ÑÓÑÒÎµÃÑÎÒ ÉÎÀÃ¶µ¶§Î²¶¤HIV§§¾¿ÑÒÀ»¿®ÉÊÎ¿CD4ÑÒ

tigen iFcR#%»ÀÉ¿¨§ÒÊ¨ÒÑÁ¨ÔÎÊ¨ Ñ§ÑÀ¶

pokazali daHIV§ÎÁÃÑ¨ÒÖ¨®¨¿Ñ¨ÃÑÀ¿É¸¨®¨

ra u endotelnim, a u mawoj meri i u mezangijskim ¤¸¨µÑ§Ñ²¸Î§¿¶¸ÑÑ¸¨Ò¨¶Ô¨À®¿Ñ¸Ò¨§É¨Ê¸ Ò¨§¤¸¨µÑ§ÑÎ¨ÉÎ¿ÃÊÎ²ÑÎÉ¼ÊµÉ¿¨ªÔÑ¤ ÒÎ§¨¼¹ ÃÑÀ¶¨§¶ÒÎª¨ÀÊÎª§¨µÀ»Ñ¾Îµ Ñ¿ÑÃ¨ dokazivawa virusnih proteinap24,p17,gp41igp120

¶Ê»¨Ô¶»ÎµµÖ¨»À¨¿ÑÒÎ¶ÖÎ¿§Ñ¸¨Ò¶¨»Ñ¸¶É¹ÒÎ ¶ÉÑ¿ÑÖ¨Ò¶»¿Ñµ ÒÉÎ¶ÓÃÑÒÑÑÒÑÀµÒÑµ¼¨¿É¿¨ ªÔÑ¤ÒÎ§¨¼¹ ÃÑµÃ¨¿»ÊÒÑ¨ÒÖ»®¨µÑ¾¶¾¿ ga sHIV§±¶HIVÉÎÓ¨Ê¨ÔÒ¨§¾Î¸ÀÒ¨®¨§Ñ´ÀÊÑ

Ñ¸¨Ò¨µÃÎÔÎ¹ÒÑÓÑÒÑÀÊÑÒÑ»ÒÖ¿ÎÉÑÊ¨µÓÑ»Îµ¶À¶ ÒÎÉªÎÃÒ¨¨Ã¿¶²¨É¿ÑÊ¤¨ÖÑ»ÊÎ¿¨ÑÒÑÀÀÓÒÑ da za razvoj nefropatije nije neophodno prisustvo Ô¨¿¶ÀÑ¶Ê»¨Ô¶¾¶¾¿²Ñ£ÒÎ¼ Ô¨¿¶ÀÒ¨ª²ÒÀ»¨ª É¿ÎÃ¶»ÑÊÑ§ÎÁÊ¿ÑÒÀÑ»Ê¨ÔÑ®¨µÎ§²ÒÑÃÎ§Ñ¤¨ÒÑ Ã¨¿»ÊÒÎ Ã¨¿»ÊÒ¨§ ÃµÀÊÔÎ§ Ô¨¿¶ÀÒ¨ª ²ÒÀ»¨ª É¿ÎÃ¶»ÑÊÑÒÑ®¨¹Ò¤¸¨µ¨¸¨¨ÒÃ¨¿»ÊÒÎ É¿»Î ÎÊÉ¶¼ÊÒ¨ª®¨ÊÎ»¨ÒÑÉÎ»¿Ò¶Ê¨ÒÑÀÊÑÒÑ»ÒÖ¿Î ÉÑÊ¨µ£ÃÑ¹§À¸Ã¶ÃÎ²Ñ±ÑµÑÃÎ¸ÑÓ¨ÃÎÑ»Ê¨Ô¨¿Ñ Ñ¾ÑÓ¨´ÒÎ²Ö¨¾¿Î¾¸ÑÀÊÒÎ²ÖÑ»ÊÎ¿Ñ¿ÑÀÊÑ bFGF) i

¾ÊÑÊ¿ÑÒÀÖÎ¿§¨¼¶¤²ÖÑ»ÊÎ¿Ñ¿ÑÀÊÑ TGFʊ°ÑÒ¨

§¹¨ÔÎµÃÑµÎ¼Ò¨µÉ¿®¨ÓÒÎÃÖ¨Ò¨ÀÑÒÑ»Ê¨ÔÒ¨ ÃÎÔ¨¿¶ÀÒÎ²²ÒÑÇ¿ÊÉÎÀÊÑÔ¹ÑÀÃÑ¶ÊÎ§À§¨À¸¶ §±¶Ô¨¿¶ÀÒ¨§É¿ÎÊ¨Ò¨§ÑÓÒÑ´ÑµÒ¶¶¸Î²¶¨§ÑÊÑÊ »Îµ¨§Î²¶ÎÀ¸Î¾Ñ±ÑÊ¨¤¸¨µ¨ÒÖ¨®¨¿ÑÒÔ¨¿¶ÀÎ§ ¦ÑÊ ÉÎÃÀÊ¨´ §Ñ»¿ÎÖÑ² »ÎÀÊÒ À¿Á¨ ÃÑ ÉÎÀÉ¼ produkcijuTGFʊ»ÑÎ¨²¸¨µÑ¸Ò¤¸¨µÃÑÉÎÔ¤Ñ

(3)

Ö»®¨µÑÊÑ»Î±§ÎÁ¨ÓÑÓÔÑÊ¨ÉÎ¿§¤Ñµ¿²¶¸Ñ®¨ µ¿ÑÓ¸¨´¨Ê¨ª®¨ÊÎ»¨ÒÑÃÎ§Ñ¤¨ÒÑ¶»¹¶´¶µ¶¤¨IL-1,

IL-6,TNF-α tumor necrosis factor alfa), kao i faktore »Îµ¨ÀÊ¨§¶¸¨¼¶»Î¸ÎÒ¨µ²¿ÑÒ¶¸Î®¨ÊÑ¨§Ñ»¿ÎÖÑ²Ñ Ë±¶Ê¨§ÎÉ¼ÊµÉ¿¨ªÔÑ¤ÒÎ§¨¼¹ ÃÑÉ¿ÎÃ¶» tiHIVvirusnih genaper seÒ¨À¶ÃÎÔÎ¹Ò¨ÃÑÀÔÎµ¨§

ÃµÀÊÔÎ§¨ÓÑÓÎÔ¶É¿Î§Ò¶Î¾¸¨»¶ÒÖ¿ÎÉÑÊ¨µÑ ¸¨¤ÃÎÉÎµÑÔÒÖ¿ÎÉÑÊ¨µ¨ÓÑÓÔÑÒÀHIVÃÎ¤¨¨¸¨

ÒÓÑÔ¨À¨ÉÎ¿ÃÉÎ§Ò¶ÊÎ²ÃµÀÊÔÑÔ¨¿¶ÀÑ¨ÎÃÀÊÑ ÑÎÃÒÎÀÒÎÎÃ²ÎÔÎ¿Ñ¨ÒÖ¨®¨¿ÑÒÎ²Î¿²ÑÒ¨Ó§Ñ ÃÎ §Ñ¤¨ÒÑÑÀª§¨É¿¨»ÑÓÑÒµ§Î²¶¤¨ÒÑÀÊÑÒÑ»Ò fropatije u sklopuHIV¨ÒÖ»®¨µ

ьѳќъдгѳќ

½ÎÃ¾Î¸ÀÒ¨»ÑÀÑHIV¨ÒÖ»®¨µÎ§»¸¨Ò¨´»¨À

§ÎÁ¨ÀÉÎ¹¨Ê¨¼¨¿Î»ÀÉ»ÊÑ¿À¨§ÉÊÎ§Ñ»Îµ¨¶»Ñ Ó¶µ¶ÒÑÎ¼Ê¤ ¾¶¾¿²ÑÑµ´¼¤ÀµÑÔ¹ÑÑ»¶ÊÒÑ ¨ÒÀ¶Ö¨®¨µÒ®¨µÑ¿ÑÃÑ¾¶¾¿²Ñ ÈÍ»ÎµÑµÎ¾¨´ÒÎ ÉÎÀ¸Ã¨®ÑÀÉÀª¨ÉÎÊÒÓ¨µ¨¸¨ÒÖ¿ÎÊÎ»À¨´Ò¨ª Ñ²ÒÀÑ½ÎÃ¨ÓÔÀÒÎ²¾¿ÎµÑ¾Î¸ÀÒ¨»Ñ§ÎÁÒÑÀÊÑÊ¨ nefropatija izazvana sHIV»ÎµÑµÀ»¸¿ÎÓ¨¿Ñµ¶¤

É¿¨¿ÎÃ ¨ À§ÑÊ¿Ñ À Î¾¸¨»Î§ ÖÎ»¶ÀÒÎÀ²§ÒÊÒ ²¸Î§¿¶¸ÎÀ»¸¿ÎÓ»ÎµÑ¨§ÑÒÑµÉ¿Î²¿À¨ÔÒ¨µ¨ÊÎ» U skorije vreme kodHIVÉÎÓ¨Ê¨ÔÒ¨ªÎÀÎ¾ÑÎÉ¨ÀÑÒ

µÒÑÀÊÑÒÑ»ÉÎÀ¾ÒÎ²Ê¨ÉÑÑ»¶ÊÒÎ²¨ÒÊ¿ÀÊ¨®¨µÀ»Î² nefritisa poznat kaoDILS³¨§ÉÊÎ§¨Î¼Ê¤ Ñ¾¶

¾¿²Ñ§Î²¶ÀµÑÔ¨Ê¨¶¾¨¸Î»ÎµÎµÖÑÓ¨HIV¨ÒÖ»®¨

µ³§Î¿ÖÎ¸Î¼»Î²ÑÀÉ»ÊÑ§±¶¿ÑÓÒÎÔ¿ÀÒ¨§ÀÔ Ê¸ÎÀÒÎ§¨»¿ÎÀ»ÎÉÀ»¨§É¿Î§ÒÑ§ÑµÃ¨ÒÎÀ¶§¨»¿Î ®¨ÀÊ¨´ÒÑÃ¨¸ÑÊÑ®¨µÑ»ÑÒÑ¸¨¤Ñ¾¸ÑÒ´Ô¨ÒÑÀÊ¨§®¨ ¸¨ÒÃ¿¨§Ñ ¨ÒÊ¿ÀÊ¨®¨µÀ»Ñ ¨ÒÖ¨¸Ê¿Ñ®¨µÑ ¨ ÖÎ»¶ ÀÒÎÀ²§ÒÊÒÑ²¸Î§¿¶¸ÎÀ»¸¿ÎÓÑ¶ÊÔ¿±Ò¨»ÎÃÔ ¤¨ÒÎ¾Î¸¸¨ªÎÀÎ¾Ñ§¶ÒÎÖ¸¶Î¿À®ÒÊÒ¨ÒÑ¸ÑÓ µÒÀÉ®¨Ö¨´ÑÒÃÎ»µÒÑ¸ÑÓ¸»Ê¿ÎÒÀ»§¨»¿ÎÀ»Î É¨µ¶Ô¸¨»Îµ§¿¨ÀÉ®¨Ö¨´ÑÒ¨É¿ÃÀÊÑÔ¹ÑÉÎ¶Ó ÃÑÒÃ¨µÑ²ÒÎÀÊ¨´»¨§ÊÎÃ

LITERATURA

1. Gasrdenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: A clinicopathologic study. Clin Nephrol 1984; 21:197-204.

2. Valeri A, Neusy AJ. Acute and chronic renal disease in hospitalized patients. Clinical Nephrol 1991; 35:110-8.

3. Rao TK, Freidman EA. Outcome of severe acute renal failure in patients with aquired immunodeficiency syndrome. Am J Kidney Dis 1995; 25:390-8.

4. D’Agati V, Suh JI, Carbone L, et al. The pathology of HIV nephrop-athy: A detailed morphologic and comparative study. Kidney Int 1989; 35:1358-70.

5. Pardo V, Bell M, Ortiz C, et al. The spectrum of glomerular lesions in patients with HIV infection [abstract]. Fed Proc 1989; 3:A1281. 6. Seney FD, Burns DK, Silva FG. Acquired immunodeficiency

syn-drome and the kidney. Am J Kidney Dis 1990; 16:1-13.

7. Mazbar SA, Schoenfeld PY, Humphreys MH. Renal involvement in patients infected with HIV: Experience at San Francisco General Hospital. Kidney Int 1990; 37:1325-30.

8. Bourgoignie JJ. Renal complications of human immunodeficiency virus type I. Kidney Int 1990; 37:1571-84.

9. Rao TK, Freidman EA, Nicastri AD. The types of renal disease in acquired immunodeficiency syndrome. N Engl J Med 1987; 316:1062-8.

10. Bourgoignie JJ, Meneses R, Ortiz C, et al. The clinical spectrum of renal disease associated with human immunodeficiency virus. Am J Kidney Dis 1988; 12:131-7.

11. Carbone L, D’Agati V, Cheng JT, Appel G. The course and progno-sis of human immunodeficiency syndrome. Am J Med 1989; 87:389-95.

12. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and seg-mental glomerulosclerosis in the acquired immunodeficiency syn-drome. N Engl J Med 1984; 310:669-73.

13. Barisoni L, Szabolcs M, Ward L, D’Agati V. Visceral epithelial cell alterations in focal segmental glomerulosclerosis [abstract]. Mod Pathol 1994; 7:157A.

14. Cohen AH, Nast CC. HIV-associated nephropathy: A unique com-bined glomerular, tubular and interstitial lesion. Mod Pathol 1988; 1:87-97.

15. Itescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltrative CD8 lymphocytosissyndrome in human immunodeficiency virus (HIV) infection: A host immune response associated with HLA-DR 5. Ann Intern Med 1990; 112:3-10.

16. Itescu S, Brancato LJ, Winchester R. A sicca syndrome in HIV infection: Association with HLA-DR5 and CD8 lymphocytosis. Lancet 1989; ii:466-8.

17. Itescu S, Rose S, Dwyer E, Winchester R. Certain HLADR5 and -DR6 major histocompatibility complex class II alleles are associat-ed with a CD8 lymphocytic host response to human immunodefi-ciency verus type I characterized by low lymphocyte viral strain heterogeneity and slow disease progression. Proc Natl Acad Sci USA 1994; 91:11472-6.

18. Radojević S, Basta-Jovanović G, Oklobdžija M, Radotić-Smiljanić K, Đorđević LJ. Morphological changes in kidney of AIDS patients and their significance in diagnostics. Archive of Oncology 2001; 9(Suppl 1).

19. Karlsson-Parra A, Dimeney E, Fellstrom B, Klarkeskog L. HIV receptors (CD4 antigen) in normal human glomerular cells. N Engl J Med 1989; 320:741.

SHEMA 1.ƸǚǡǠǤǗǤǚǩǜǑǡǑǤǠǔǗǟǗǙǑǟǗǦǢǠǡǑǤǚǹǗǚǙǑǙǓǑǟǗǣHIV

SCHEME 1. Hypothetical pathogenesis of nephropathy caused by HIV.

VIRUSNA INFEKCIJA

ǍƨƮƫǊƨƲƢƳƨưƸƫƯƢƣƶƣƳƨƥƢ ƫưƵƳƢƳƨưƢƮưƫƮƫƯƷƱƹƫƵƫ_{ƫƯƱưƱƹƫƵƫ} ƮƫƯƷƱƹƫƵƫƫƯƱưƱƹƫƵƫ_{ƶƹƫƳƭƶƮƢƹƫǊƫ}

ƹƫƵƱƲƢƵƫƺưƫƨƷƨƭƵƫ ƱƣƳƢƧƢƲƳƱƧƶƭƢƵƢ_{ƤƫƳƶƴưƫƸƥƨưƢ} ƫưƧƶƭƹƫǊƢƹƫƵƱƭƫưƢ_{ƧƱƯƢǍƫưƢ}

(4)

ABSTRACT

HIV- (Human Immunodeficiency Virus) infected patients may be faced with a variety of renal problem patterns. Acute renal failure is common and most often the result of sepsis, hypertension, and toxic agents. Besides acute renal failure, HIV-associated nephropathy occurs in many HIV-positive patients, representing a unique pattern of sclerosing glomerulopathy. Many authors consider it to be the most rapidly progressive form of focal segmental sclerosis.

Key words: HIV; HIV-associated nephropathy; focal segmental glomerulosclerosis; acute renal failure

Gordana BASTA-JOVANOVIĆ Takovska 21, 11000 Beograd Tel: 011 769 027

HIV INFECTION AND THE KIDNEYS (PART I)

Gordana BASTA-JOVANOVIĆ

Institute of Pathology, School of Medicine, University of Belgrade, Belgrade